Dermata

Scientifically proven dermatologic solutions

Corporate Presentation
2025

FORWARD LOOKING STATEMENTS AND DISCLAIMERS

This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to prioritize OTC dermatology products; the anticipated benefits of the strategic shift; the anticipated benefits of Dermata’s strategic shift, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned or future OTC product launches; and other factors described in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

PROPRIETARY INFORMATION

dermata

Experienced Management Team and Board

Senior Management

Gerry Proehl
Chairman, President, and CEO

Kyri Van Hoose, C.P.A., MBA
SVP, Chief Financial Officer

Maria Bedoya Toro Munera, Ph.D.
SVP, Regulatory Affairs & Quality Assurance

Chris Nardo, M.P.H., Ph.D.
SVP, Chief Development Officer

Board of Directors

Gerry Proehl
dermata

Wendell Wierenga Ph.D.
SANTARUS, INC.®

Steven J. Mento, Ph.D.
Histogen

Andrew Sandler, M.D.
ALPINE Immune Sciences

David Hale
Hale BioPharma Ventures, LLC.

Kathleen Scott
ARS PHARMA

Mary Fischer
colorescience®

Brittany Bradrick
NEURELIS™

Corporate Highlights

- Recent **pivot** to develop and distribute Over-the-Counter pharmaceutical skincare products
- ***Spongilla* technology** as a platform to treat medical and aesthetic skin diseases & conditions
- **Large** over-the-counter **dermatology** market opportunities
- First once-weekly acne kit with launch expected in mid-2026

US Acne Market

Prevalence

~50M

Market Size

~$3.8B (projected 2026)

Opportunity Highlights

- 85% of teenagers
- 64% of 20-29 years
- 43% of 30-39 years
- Over 70% of acne patients first seek OTC products
- No other once-weekly OTC acne treatment options
- Patients are seeking more convenient treatment options
- Potential expansion into back and chest acne

dermata

Other Dermatology Market Opportunities

	Aesthetics w/ Botulinum Toxin	Psoriasis	Seborrheic Dermatitis/Dandruff
US Prevalence	**~13.1M**$_{(procedures)}$	**~7.5M**	**~1-3%**
Market Size	**~$12B**	**~$9.7B**$_{(US\ 2020)}$	**~$512M**$_{(US)}$
Opportunity Highlights	Almost 9.5 million procedures with neuromodulators • Average cost of one session is $435 • Untapped markets where neuromodulators are rarely used	• 80% have mild-to-moderate disease • Few topical OTC psoriasis products	• 90% of patients report an impact on self-esteem

dermata

Multi-use *Spongilla* Technology

Spongilla Technology

- Can be used across medical and aesthetic skin conditions
- Complex freshwater sponge, contains unique characteristics, optimized for skin care
- Possesses multiple complementary chemical and mechanical properties to potentially enhance pharmaceutical treatment effect
- Use as a standalone product or for needle-free topical application of large molecules for intradermal delivery



Multiple Components

Chemical Components:

- Anti-inflammatory
  - Reduction of C. *acnes* stimulated IL-8 production in NHEK
  - Inhibition of IL-17A and IL-17F expression in human cell lines
- Anti-microbial activity against C. *acnes*
- Effects on sebum production, namely inhibition of lipogenesis in sebocytes

Mechanical Component: uniquely sized siliceous spicules that exfoliate the dermal epithelium:

- Create microchannels into the dermis
- Opening closed comedones (blackheads)
- Promoting collagen production

dermata

Recent Strategic Transition

- Leverage Existing Science
  - Years of clinical experience with *Spongilla* technology
  - Build consumer credibility through a scientific foundation
- Multi-use product line with once-weekly dosing
- Ability to expand portfolio into other indications
  - Focus on overall skin health, by developing multiple potential product lines
- Go-to-Market Focus
  - Direct-to-consumer sales
  - B2B direct to estheticians and dermatologists
  - No reliance on prescriptions or insurance reimbursement

OTC vs. Prescription Market Benefits

Speed

- Fewer regulatory hurdles
- Fewer development restraints
- Real time innovation
- Quicker time to revenue

Cost

- Significantly less cost of development
- Sales force optional
- Decreased cost for many patients

Accessibility

- Broader markets
- No prescriptions
- No insurance
- Direct-to-consumer
- B2B
- Personalized skin care

dermata

OTC Marketing Strategy

Branding

- Branding agency developing a brand identity that speaks to the ancestral innovation of *Spongilla* technology
- Create community of consumers that buy into the long-term effects of the treatments
- Leverage *Spongilla* technology as the foundation for consumer skin care that is backed by science

DTC

- Create a custom website with a subscription purchasing model
- Leverage niche influencers
- Build pre-launch anticipation
- Develop an organic social campaign

B2B

- Over 48,000 estheticians in the US
- Create an esthetician advisory board
- Offer a specialized training certificate
- Utilize network of esthetician influencers as a sales force
- Kit is a mid-tier in-office procedure

dermata

Acne Kit

Expected Launch
Mid-2026

OTC Acne Kit – 1 month supply of weekly treatments

- 4 Salicylic acid* wipes 0.5%
- 4 x 1 gram of *Spongilla* lacustris purified powder
- 4 x 3 mL of 3.0% Hydrogen peroxide

*Salicylic acid – OTC monograph MO32 – approved for acne, psoriasis, seborrheic dermatitis/ dandruff at various concentrations

dermata

OTC Acne Kit

Step 1

Patient wipes face with Salicylic Acid wipe

Step 2

Sponge powder is mixed with H_2O_2

+

Step 3

Patient applies sponge mixture as a mask once per week



dermata

Potential Acne Kit Benefits

Frequency of Treatments

- Current topical treatments require one or two applications daily, resulting in poor compliance and early discontinuation
- **Once weekly application may optimize compliance**

Time to Treatment Effect

- Current topical treatments may take 6-8 weeks before a patient perceives treatment effect
- **Acne kit may begin to reduce inflammatory lesions after only one treatment**

Tolerability and Side Effects

- Current products have multiple side effects and tolerability issues occurring well before a treatment effect
- **Anticipated excellent tolerability and side effect profile**

dermata

Phase 1 OTC Acne Kit Study: Expected start Q1’2026

OTC Acne Program Overview:

- Open-label study of once-weekly application of acne kit for the treatment of mild-to-moderate acne

Study Details and Eligibility

- Patients 12 years and older
- Patients must have an IGA baseline score of 2, 3 or 4 (mild – severe)
- 12-Week study duration
- **Once weekly** application
- Weekly photographs

Endpoints

- Subject Satisfaction Score
- Subject Global Assessment
- Post Inflammatory Hyperpigmentation and Severity Score
- Absolute Reduction in Inflammatory Lesion Counts
- Absolute Reduction in Non-inflammatory Lesion Counts
- Investigator Global Assessment

dermata

Spongilla Technology Phase 3 Acne Study: Positive Topline Results

Rx Acne Program Overview:

- Positive results from STAR-1 study in acne of *Spongilla* technology were announced in March 2025

Study Details and Eligibility

- Patients 9 years and older
- Patients must have an IGA baseline score of 3 or 4 (moderate or severe)
- 12-Week study duration
- **Once weekly** application

Endpoints

- Absolute Reduction in Inflammatory Lesion Counts
- Absolute Reduction in Non-inflammatory Lesion Counts
- Investigator Global Assessment (IGA Scale = 0 to 4)
  - Responder classified as 2-Grade reduction and 0 or 1 (clear or almost clear)

***Same three primary endpoints as measured in the Phase 2b study**

dermata

STAR-1 Phase 3 Results: Treatment Emergent Adverse Events Considered Related to Study Drug by System Organ Class

Adverse Event	XYNGARI n=341	Placebo n=177
Subjects reporting at least one TEAE	7 (2.1%)	1 (0.6%)
General and Administration Site Conditions	7 (2.1%)	1 (0.6%)
Application Site Pain	3 (0.9%)	0 (0.0%)
Application Site Irritation	2 (0.6%)	1 (0.6%)
Application Site Erythema	2 (0.6%)	0 (0.0%)
Application Site Pruritus	1 (0.3%)	1 (0.6%)
Application Site Paraesthesia	1 (0.3%)	0 (0.0%)
Application Site Swelling	1 (0.3%)	0 (0.0%)

STAR-1 Phase 3 Results: Local Tolerability 1 Week Post-Treatment – Day 85











dermata

STAR-1 Phase 3 Acne Results: Lesion Counts

Mean Change from Baseline



Inflammatory Lesions



Non-Inflammatory Lesions

Percent Change from Baseline





* p < 0.05
** p < 0.01
*** p < 0.001

dermata

STAR-1 Phase 3 Results: Investigator's Global Assessment



*ITT Population

dermata

Inflammatory lesions change from baseline across three well-controlled studies shows consistency of effect

	XYNGARI Phase 2a (n=31)	XYNGARI Phase 2b (n=91)	XYNGARI STAR-1 (n=341)
Baseline[1]	26.0	25.0	25.0
Week 4	-11.7	-11.3	-11.4
Week 8	-14.3	-13.6	-14.7
Week 12	-15.8	-15.6	-16.8

1 – Median Baseline Inflammatory Lesion Count

Spongilla Technology

Enabling Topical Application of Botulinum Toxin



Overview

Regimen for topical Botulinum Toxin

Spongilla technology creates millions of microchannels **for topical delivery of botulinum toxin** to the dermis



* Spicules average about 200 µm in length, 10-15 µm in diameter



Sponge mixture creates millions of microchannels in the human skin

Simple Application Process

Step 1: Sponge mixture is massaged into the treatment area:

- **Creates microchannels through the stratum corneum into the dermis**

Step 2: Sponge mixture is then removed after 10-15 minutes

Step 3: Botulinum toxin liquid formulation is massaged into the treatment area, utilizing newly created microchannels



dermata

Topical vs. Injections for Delivery of Botulinum Toxin

Molecule Size

Injection Limitation

- Botulinum toxin molecules are between 150-900 kDa and are currently injected for clinical efficacy

Topical Benefit

- **Creation of microchannels in the skin allows topical penetration of botulinum toxin into the dermis**

Increased Coverage

Injection Limitation

- Botulinum toxin injections limit the spread over a large surface area

Topical Benefit

- **The creation of millions of microchannels allow a uniform topical application of toxin to more easily deliver treatment to a larger surface area**

No Injections Necessary

Injection Limitation

- Current treatments, like hyperhidrosis, require 10-20 injections in each axilla that can be painful for patients

Topical Benefit

- **Topical application had favorable tolerability in clinical trials**

Additional Uses

Injection Limitation

- Difficulty of intradermal injections limits uses

Topical Benefit

- **Topical delivery could expand the potential indications for botulinum toxin**
  - **Global Aesthetics, Acne, Acne Scars, Hyperhidrosis**

dermata

Phase 1b Facial Aesthetics Completed

Study Design

- Open-label
- 10 adult patients received a single, sequential topical application of:
- **One application of sponge powder, followed by one topical application of BOTOX®(64U)**
- Patients assessed at Week 4, Week 8, Week 12 and Week 16 post application

Endpoints

- Reduction of:
  - Glabellar Lines
  - Forehead Lines
  - Lateral Canthal Lines
  - Fine Lines
  - Pore Size
  - Sebum Production
- Improvements in:
  - Luminosity and brightness
  - Improvements in Global Aesthetic scale

Key Findings

- Well-tolerated and produced no potential distant spread of toxin events
- Demonstrated improvements in luminosity, brightness, and global aesthetics
- Reduced pore size, sebum production, and fine lines

dermata

Phase 1b Aesthetics: Canfield VISIA Image Analysis Change from Baseline to Month 1

Measure	Forehead		Left Temple		Right Temple	
	Mean Change	Pct Change	Mean Change	Pct Change	Mean Change	Pct Change
Pore Count	-107.5	-12.2%	-14.8	-11.1%	-21.3	-19.0%
Pore Area	-5.2	-16.4%	-1.7	-10.0%	-2.0	-16.5%
Wrinkle Count	-12.2	-11.6%	-3.2	-18.9%	-3.4	-19.0%
Wrinkle Area	-11.7	-7.0%	-4.1	-13.5%	-5.1	-14.1%

Phase 1b Aesthetics: Canfield VISIA Pore Analysis from Baseline to Month 1

Baseline



Data Point	Value
Pore Count	302
Pore FA	0.77

Visit 4



Data Point	Value
Pore Count	100
Pore FA	0.32

Subject 013

dermata

Phase 1b Axillary Hyperhidrosis Completed

Study Design

- Open-label
- 10 adult patients (20 axillae) enrolled at one site in the US
- 4-Week study duration
- **One application of sponge powder, followed by one topical application of BOTOX®(100U)**

Endpoints

- Percent of patients with ≥50% reduction in gravimetrically measured sweat production from baseline
- Percent of patients with gravimetric sweat production of ≤50mg
- Percent change in gravimetric sweat production

Phase 1b Results: Reduction in Sweat Production

	DMT410 (N=20) Response Rate
Decrease in gravimetric sweat production ≥ 50%	80%
Gravimetric sweat production <50mg	85%
Change in gravimetric sweat production	-75%

dermata

Potential Follow-on OTC Indications

Mild to Moderate Psoriasis

- Salicylic acid* is on the OTC monograph for the treatment of Psoriasis at 1.8%-3.0%
- Potential to offer a twice weekly treatment with salicylic acid and *Spongilla lacustris* powder
- Develop a new kit specifically for treatment of psoriasis

Back/Chest Acne Regimen

- Kit would contain a 0.5% salicylic acid wipe, 2g of *Spongilla* powder, and 6ml of H_2O_2
- Kit would be sold as a monthly treatment with 4 weeks of treatments

Acne Spot Treatment

- Could formulate a salicylic acid gel with a concentration of *Spongilla* for acne spot treatment

Dandruff or Seborrheic Dermatitis

- Multiple drugs, including Salicylic acid, listed on OTC monograph for treatment of seborrheic dermatitis/dandruff

*Salicylic acid – OTC monograph MO32 – approved for acne, psoriasis, seborrheic dermatitis, dandruff

Potential Uses of *Spongilla* technology

- **Potential alternative to microneedling**
  - skin rejuvenation
  - Reduction in skin hyperpigmentation
- **Assist with topical delivery of botulinum toxin**
  - Facial aesthetics (reduce pore size/number, sebum production, fine lines, tighten and improve look of skin)
  - Hyperhidrosis (axillary, palmar, plantar)
  - Acne – potential for improved results due to reduction in sebum production and pore size
  - Rosacea – potential for reduction in facial redness
- **Broaden delivery of Hyaluronic Acid dermal fillers to entire face**

IP Overview

Patents

- Issued:
  - *Spongilla* combination for acne
    - USA
  - *Spongilla* combination with botulinum toxin for hyperhidrosis
    - Japan and Australia
- Applications:
  - *Spongilla* combination as a single entity
    - Treatment of acne
  - *Spongilla* combination with botulinum toxin
    - Treatment of hyperhidrosis
    - Treatment of aesthetic skin conditions
    - Treatment of acne

Supply

- Signed an exclusive supply agreement with the largest known supplier of *Spongilla lacustris*
  - *Spongilla* regrows each year
- Favorable COGS
- Harvesting and Manufacturing trade secrets

dermata

Dermata Therapeutics

Scientifically proven, dermatologic solutions